98%
921
2 minutes
20
Objective: To clarify the association of the aortopulmonary collaterals (APCs)/venovenous collateral (VVCs) in patients with plastic bronchitis (PB) after the Fontan procedure.
Methods: All patients who underwent total cavopulmonary connection from 1994 to 2022 were reviewed. APCs/VVCs were detected using angiography. The impact of APC/VVCs, as well as other variables on the onset of plastic bronchitis, was evaluated.
Results: A total of 635 patients were included. Plastic bronchitis was observed in 15 (2.4%) patients, and the median duration between total cavopulmonary connection and the onset of plastic bronchitis was 1.1Â years. Freedom from PB at 5 and 10Â years was 97.5% and 96.5%, respectively. As for the association of PB and APCs/VVCs, patients with PB had an increased incidence of post-total cavopulmonary connection APCs (60% vs 14%, PÂ <Â .001) and VVCs (53% vs 14%, PÂ <Â .001). Freedom from PB was the lowest in the patients who were associated with both APCs and VVCs after total cavopulmonary connection. APCs after total cavopulmonary connection (PÂ =Â .002; hazard ratio, 5.729), VVCs after total cavopulmonary connection (PÂ =Â .016; hazard ratio, 3.527), and chylothorax (PÂ =Â .019; hazard ratio, 3.662) were identified as independently associated factors with the onset of PB.
Conclusions: The occurrence of post-Fontan APCs and VVCs was significantly associated with the development of PB. Treatment or mitigation of collaterals may represent an opportunity to prevent the development of PB, a remaining source of post-Fontan excess morbidity and mortality.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jtcvs.2024.09.049 | DOI Listing |
Pharmacotherapy
September 2025
Division of Pediatric Cardiology, Department of Pediatrics, University of Michigan Health System, Ann Arbor, Michigan, USA.
Introduction: Pediatric plastic bronchitis (PB) is a rare complication of surgically palliated congenital heart disease (CHD). Fibrin casts obstruct airways and can cause respiratory distress. There are no therapeutics approved by the United States Food and Drug Administration to treat PB, but inhaled tissue plasminogen activator (tPA) has been anecdotally used to relieve symptoms.
View Article and Find Full Text PDFCirc Cardiovasc Interv
September 2025
Division of Cardiology (Y.D., E.P., L.B., M.J.G., R.C., J.T., M.L.O.B., D.V., A.G.D.W., E.F., R.S., J.J.R., C.L.S.), Children's Hospital of Philadelphia, PA.
Background: External drainage of the thoracic duct can temporarily reduce tissue congestion and improve symptoms in patients with heart failure. However, loss of fluid limits the duration of this approach. Here, we report on our initial experience with thoracic duct drainage and autotransfusion in patients with elevated central venous pressure.
View Article and Find Full Text PDFJ Formos Med Assoc
September 2025
Department of Pediatrics, Peking University International Hospital, Beijing, China. Electronic address:
Pediatr Dermatol
August 2025
Department of Dermatology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
An 8-year-old female developed fever, dyspnea, and cough 1 week after starting ustekinumab for psoriasis. She was noted to have recurrent left lower lobe consolidation and subsequent obstructing eosinophilic casts and was diagnosed with eosinophilic plastic bronchitis. Her respiratory symptoms improved with systemic steroids, mepolizumab for 10 months, and discontinuing ustekinumab.
View Article and Find Full Text PDFBMC Infect Dis
August 2025
Department of Pediatrics, The First Affiliated Hospital of Xinxiang Medical University, No.88 of JianKang Road, Weihui, Henan province, 453100, China.
Objective: To explore the clinical characteristics and independent risk factors of pneumococcal pneumonia complicated with plastic bronchitis.
Methods: 156 patients with pneumococcal pneumonia who were admitted to the Department of Pediatrics of the First Affiliated Hospital of Xinxiang Medical University. The patients were divided into plastic bronchitis (PB) group and non-plastic bronchitis (non-PB) group.